| Followers | 318 |
| Posts | 55275 |
| Boards Moderated | 12 |
| Alias Born | 08/19/2009 |
Tuesday, December 07, 2021 10:27:48 AM
Amen!
Recent MRK News
- Merck’s Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke • Business Wire • 04/28/2026 10:45:00 AM
- Futures Suggest Flat Start for Wall Street: Dow Jones, S&P, Nasdaq • IH Market News • 04/27/2026 01:13:41 PM
- Futures Indicate Muted Start for Wall Street: Dow Jones, S&P, Nasdaq • UK Market News • 04/27/2026 01:13:31 PM
- Organon Jumps 15% as Sun Pharma Agrees $11.8bn Buyout • IH Market News • 04/27/2026 10:11:06 AM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 04/24/2026 11:30:33 AM
- Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc. • Business Wire • 04/24/2026 10:45:00 AM
- Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation • PR Newswire (US) • 04/22/2026 12:00:00 PM
- FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir) • Business Wire • 04/21/2026 06:11:00 PM
- Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) • Business Wire • 04/21/2026 10:45:00 AM
- FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer • Business Wire • 04/20/2026 10:48:00 AM
- European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season • Business Wire • 04/17/2026 11:49:00 AM
- New Survey Shows HPV Awareness Isn't Keeping Pace with Certain HPV-Related Cancer Trends in Canada • PR Newswire (Canada) • 04/15/2026 11:00:00 AM
- Un nouveau sondage révèle que la sensibilisation au VPH ne suit pas le rythme de certaines tendances en matière de cancers liés au VPH au Canada • PR Newswire (Canada) • 04/15/2026 11:00:00 AM
- Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy • Business Wire • 04/13/2026 11:00:00 AM
- Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy • Business Wire • 04/13/2026 11:00:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/08/2026 08:32:02 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/08/2026 08:28:33 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/08/2026 08:25:08 PM
- Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc. • Business Wire • 04/07/2026 01:00:00 PM
- Form SC TO-T - Tender offer statement by Third Party • Edgar (US Regulatory) • 04/07/2026 11:00:59 AM
- Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration • Business Wire • 04/02/2026 10:50:00 AM
- European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens • Business Wire • 04/02/2026 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 05:47:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 05:44:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 05:42:51 PM
